Therapeutic outcomes of the LHRH antagonists

ABSTRACT

Introduction: Recently, LHRH antagonists have been established in the management of advanced prostate cancer, although the vast majority of Medical Oncologists and Urologists still prefer the LHRH agonists.

Areas Covered: In this article we assess the therapeutic outcomes and the safety of the LHRH antagonists (mainly degarelix) compared to the LHRH agonists.

Expert Commentary: Relevant studies demonstrated that LHRH antagonists are at least non-inferior to the LHRH agonists regarding therapeutic efficacy and safety, while there is potential benefit over the LHRH agonists in terms of cardiovascular morbidity and disease control. Disadvantages regarding formulation and frequency of administration are currently seem to be improving, as a 3-month depot of degarelix is evaluated and relugolix, an investigational orally administered is undergoing phase I studies, while the results of relative comparative studies are warranted.

KEYWORDS:

• Prostate cancer
• LHRH antagonist
• LHRH agonist
• degarelix
• relugolix
• abarelix

Declaration of Interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose

Additional information

Funding

This paper was not funded.